MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 3, 2007, Pages 251-256

  Osian, Gelu ^a,b   Procopciuc, Lucia ^b   Vlad, Liviu ^a  

^a 3rd Surgical Clinic

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Colorectal cancer; MTHFR polymorphism; Prognosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; DNA METHYLATION; DNA REPAIR; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; PREVALENCE; PROGNOSIS;

AGED; ALLELES; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; RISK; RISK FACTORS;

EID: 34948905809     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. Biochem Biophys Res Commun 1993; 193: 1184-1190.
2. Jacob RA, Gretz DM, Taylor PC et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr 1998; 128: 1204-1212.
3. Blount BC, Ames BN. Analysis of uracil in DNA by gas chromatography - mass spectrometry. Anal Biochem 1994; 219: 195-200.
4. Blount BC, Mack MM, Wehr CM et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A 1997; 94: 3290-3295.
5. Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002; 132(8S): 2413S-2418S.
6. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 1999; 10: 66-88.
7. Counts JL, Goodman JI. Hypomethylation of DNA: a nongenotoxic mechanism involved in tumor promotion. Toxicol Lett 1995; 82-83: 663-672.
8. Pogribny IP, Miller BJ, James SJ. Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. Cancer Lett 1997; 115: 31-38.
9. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-8686.
10. Whitehall V, Walsh MD, Young J et al. Methylation of 0-6-methylguanine DNA methyltransferase characterises a subset of colorectal cancer with low level DNA microsatellite instability. Cancer Res 2001; 61: 827-830.
11. Esteller M, Toyota M, Sanchez-Cespedes M et al. Inactivation of the DNA repair gene 0-6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-2371.
12. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
13. Schroeder M, Mass MJ. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 1997; 235: 403-406.
14. Hiltunen MO, Alhonen L, Koistinaho J et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer 1997; 70: 644-648.
15. Quinlivan EP, Davis SR, Shelnutt KP et al. Methylenetetrahydrofolate reductase 677C->T polymorphism and folate status affect one-carbon incorporation into human DNA deoxynucleosides. J Nutr 2005; 135: 389-396.
16. Kapiszewska M, Kalemba M, Wojciech U, Milewicz T. Uracil misincorporation into DNA of leukocytes of young women with positive folate balance depends on plasma vitamin B12 concentrations and methylenetetrahydrofolate reductase polymorphisms. A pilot study. J Nutr Biochem 2005; 16: 467-478.
17. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
18. Brockton NT. Localized depletion: the key to colorectal cancer risk mediated by MTHFR genotype and folate? Cancer Causes Control 2006; 17: 1005-1016.
19. Frosst P, Blom HJ, Milos R, Goyette P et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
20. van der Put NM, Gabreels F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
21. Ulrich CM, Kampman E, Bigler J et al. Lack of association between the C677T MTHFR polymorphism and colorectal hyperplastic polyps. Cancer Epidemiol Biomarkers Prev 2000; 9: 427-433.
22. Chen J, Giovannucci E, Kelsey K et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4864.
23. Molloy AM, Mills JL, Kirke PN et al. Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and microbiological assays. Clin Chem 1998; 44: 186-188.
24. Kono S, Chen K. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci 2005; 96: 535-542.
25. Ma J, Stampfer Mj, Hennekens CH et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-1102.
26. Chen J, Giovannucci E, Hankinson SE, et al. A prospective study of methylenetetra-hydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998; 19: 2129-2132.
27. Park KS, Mok JW, Kim JC. The 677C > T mutation in 5,10- methylenetetrahydrofolate reductase and colorectal cancer risk. Genet Test 1999; 3: 233-236.
28. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 513-518.
29. Ulrich CM, Kampman E, Bigler J et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999; 8: 659-668.
30. Levine AJ, Siegmund KD, Ervin CM, et al. The methylenetetrahydrofolate reductase 677C->T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2000; 9: 657-663.
31. Marugame T, Tsuji E, Inoue H et al. Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett 2000; 151: 181-186.
32. Le Marchand L, Donion T, Hankin JH et al. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002; 13: 239-248.
33. Chen J, Ma J, Stampfer MJ et al. Linkage disequilibrium between the 677C7gt;T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer. Pharmacogenetics 2002; 12: 339-342.
34. Sharp L, Little J, Brockton et al. Dietary intake of folate and related micronutrients, genetic polymorphisms in MTHFR and colorectal cancer: a population-based case-control study in Scotland J Nutr 2002; 132(11S): 3542S.
35. Keku T, Millikan R, Worley K et al. 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev 2002; 11: 1611-1621.
36. Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE. The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1198-1203.
37. Kim DH, Ahn YO, Lee BH et al. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett 2004; 216: 199-205.
38. Kawakami K, Ruszkiewicz A, Bennett G et al. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003; 9: 5860-5865.
39. Cohen V, Panel-Raymond V, Sabbaghian N et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
40. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785-792.